Lidia Fonseca

Lidia Fonseca is the Executive Vice President, Chief Digital and Technology Officer at Pfizer, responsible for the enterprise-wide digital strategy. Lidia leads all digital, data and technology products and solutions across the company, including digitizing drug discovery, clinical development, manufacturing, distribution and commercial. Her team accelerates innovation at Pfizer by enhancing operational processes through automation and robotics, and delivering powerful insights with data, advanced analytics, and artificial intelligence (AI) for better and faster decision-making. She is also responsible for Pfizer Learning and Development and Business Process Excellence.

As the intersection of Digital and healthcare expands, Lidia is spearheading the effort to improve patient health outcomes through innovative digital health, medicines, and diagnostics products. Under her leadership, Pfizer launched the Digital Companion™, a suite of digital products and solutions to deepen engagement between patients and physicians. She is also leading the effort to introduce AI-powered predictive algorithms to help disease suspicion, treatment optimization and adherence.

Lidia led the Digital team in Pfizer’s critical efforts to help accelerate the development of a COVID-19 vaccine, Cominarty, in less than one year, as well as the oral treatment, Paxlovid, driving innovations across the entire value chain from research to the clinical trials, to manufacturing, distribution and patient engagement. Under her leadership, Pfizer has automated over 90 percent of 100 million transactional processes across the company and Lidia’s team launched the Pfizer Learning Academy, providing learning, training, and development for all Pfizer employees.

Lidia has 20+ years of experience in the healthcare industry. In her prior role, Lidia was the Senior Vice President and CIO at Quest Diagnostics, the world’s leading provider of diagnostic information services serving one in three American adults each year, and half the physicians and hospitals in the U.S. She was responsible for technology, informatics and digital solutions. She led the effort to create Quest's innovative Quanum Solutions brand of healthcare IT and data analytics offerings that deliver critical insights to improve quality outcomes and patient care while lowering costs.

Lidia has received numerous awards and accolades, including being named on the 2022 Forbes CIO Next List recognizing the top 50 tech leaders who are redefining the CIO role and driving game-changing innovation. She was named to the 50 Most Powerful Latinas in 2020 and 2021 by the Association of Latino Professionals for America. In 2022, Pfizer won multiple awards in digital manufacturing including the CIO 100 award for digital innovation in manufacturing, the Manufacturing Leadership Award for digital supply chain innovation from the Manufacturing Leadership Council, and Gartner’s Supply Chain Breakthrough of the Year Award. She was named 2020 Healthcare Influencer and 2019 Healthcare Transformer by Medical, Marketing & Media and received the 2017 Forbes CIO Innovation Award that recognizes CIOs who lead revenue enhancing innovation efforts.

Lidia is a member of the Board of Directors of Medtronic (NYSE: MDT), Tegna, Inc. (NYSE: TGNA), and the U.S.-Japan Business Council. She was previously a member of the Board of Directors of Gannet, Inc. (NYSE: GCI) from 2014-2017 and Q2 Solutions, a joint venture between Quest Diagnostics and IQVIA, from 2016 to 2018.

She earned a bachelor’s degree from the University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business.